The Bid & Ask

Quotations, Dispatches, and the Daily Tape

Friday, August 14, 2026

Subject of the day

IART

Concerning the House

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

United States · www.integralife.com

The Long Run

FY 2010–2025 · 16 years

LineLatestCAGRTrend
Revenue$1.61B+5.4%
Gross profit$230.78M+7.9%
Operating income-$493.37M+7.6%
Net income-$516.47M+10.2%
Cash from ops$50.38M-2.4%
Quotation

$18.24

+0.86 (+4.9%)

52w hi$19.85
52w lo$8.90
Vol795.06K
As ofAug 13
The Verdict

Hold

Our score +0.28

Short+0.29
Medium+0.40
Long+0.00

computed 2026-08-13

By the Numbers

Integra LifeSciences Holdings Corporation

Healthcare · Medical Devices

Market cap$1.42B
Enterprise value$3.13B
Trailing P/E
Forward P/E7.00x
EV / EBITDA9.87x
P / S (ttm)0.86x
Profit margin-0.4%
Return on equity-0.7%
Revenue growth+0.8%
Earnings growth
Debt / equity196.49
Risk Metrics
Beta vs SPX1.45
Corr SPX0.39
Annual vol60.9%
Annual ret+9.7%
Sharpe0.16
Max DD-66.7%

Window: 504 trading days (504 obs)

Layer Breakdown
LayerRawContribution
Fundamental+0.06
Sector+0.12
Technical+0.22
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-08-13

Recent Sessions
DateOpenHighLowCloseVol
Aug 13$17.95$18.65$17.94$18.24795.06K
Aug 12$17.51$17.51$17.00$17.38469.60K
Aug 11$17.19$17.78$17.19$17.37609.90K
Aug 10$17.22$17.52$17.00$17.07686.20K
Aug 7$17.25$17.62$16.99$17.25637.40K